In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Jianjun Gao, MD, PhD
Advertisement
Articles by Jianjun Gao, MD, PhD
Advertisement
Latest Updated Articles
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerPublished: January 17th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
3
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
4
EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma
5
